News | February 05, 2025
Pfizer reports 2024 revenues 7% higher at $63.6 billion
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Q3 FY25 revenue up 24% to Rs 3,230 crore
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Acquisition expands high-value medical platform
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
Subscribe To Our Newsletter & Stay Updated
